Why GSK (GSK) is a Top Momentum Stock for the Long-Term

GSK (GSK) is identified as a momentum play, despite its Zacks Rank #3 (Hold), due to a strong VGM Score of A and a Momentum Style Score of B. The pharmaceutical company's shares have advanced 3.2% over the past four weeks, underpinned by four upward revisions to fiscal 2025 earnings estimates, raising the consensus to $4.39 per share, and an average earnings surprise of +8.8%. This combination of positive analyst sentiment, earnings performance, and price action positions GSK as a notable consideration for investors.

Analysis

GSK plc (GSK) presents a nuanced investment profile, characterized by strong momentum indicators despite a neutral Zacks Rank #3 (Hold) rating. The stock's positive momentum is evidenced by a 3.2% price appreciation over the past four weeks, which is underpinned by favorable shifts in analyst sentiment. Specifically, four analysts have revised their fiscal 2025 earnings estimates upward within the last 60 days, leading to a $0.05 increase in the Zacks Consensus Estimate to $4.39 per share. This trend is further supported by the company's robust performance history, which includes an average positive earnings surprise of 8.8%. While the primary Zacks Rank is neutral, the stock's strong secondary scores—a Momentum Style Score of 'B' and an overall VGM Score of 'A'—are highlighted as indicators of potential outperformance, suggesting that current price and earnings trends are favorable.

Key Decisions for Investors

• Momentum-focused investors may find GSK attractive, as the combination of recent price appreciation (+3.2% in four weeks) and positive upward revisions to FY2025 earnings estimates validates a bullish trend.
• Despite the neutral 'Hold' rating, the strong 'A' grade on the composite VGM (Value, Growth, Momentum) score and a history of significant earnings beats (+8.8% average) suggest underlying fundamental strength that warrants deeper due diligence for a potential portfolio addition.
• Investors should weigh the positive momentum and earnings revision trends against the primary Zacks #3 'Hold' rank, which implies the stock is expected to perform in line with the market, suggesting that the current positive signals may already be partially priced in.